Last updated: February 19, 2026
Eliquis Patent Landscape
Eliquis (apixaban), developed by Bristol Myers Squibb and Pfizer, is a direct oral anticoagulant. Its primary patent protection is set to expire in the coming years, introducing significant market shifts. The key U.S. compound patent, U.S. Patent No. 7,329,664, is scheduled to expire on October 14, 2026. Additional formulation and method-of-use patents extend protection for specific applications, but the core composition of matter patent is the primary driver of generic entry.
| Patent Type |
Patent Number |
Expiration Date (U.S.) |
Description |
| Compound Patent |
7,329,664 |
October 14, 2026 |
Core composition of matter for apixaban. |
| Method of Use (NVAF) |
8,034,835 |
June 19, 2027 |
Treatment of non-valvular atrial fibrillation. |
| Formulation Patent |
8,173,667 |
July 15, 2028 |
Specific tablet formulation. |
| Method of Use (DVT/PE) |
9,173,879 |
December 14, 2031 |
Treatment and prevention of DVT/PE. |
Source: USPTO Patent Database, Company Filings.
The expiration of U.S. Patent No. 7,329,664 permits generic manufacturers to begin producing and marketing apixaban. The legal framework governing such introductions is primarily the Hatch-Waxman Act, which facilitates the approval of Abbreviated New Drug Applications (ANDAs) for generic equivalents once the reference listed drug's exclusivity periods have expired [1].
Market Entry of Generic Apixaban
The U.S. market for apixaban is substantial. In 2022, Eliquis generated approximately $19.1 billion in worldwide sales, with the U.S. accounting for a significant portion [2]. The entry of generics is anticipated to lead to a rapid decline in Eliquis's market share and average selling price (ASP).
Generic manufacturers are expected to file ANDAs once eligible. The first-to-file (FTF) generic challenger often receives a 180-day period of market exclusivity, during which no other generics can be approved [3]. This exclusivity can incentivize early filings and create a concentrated initial generic market.
Key Factors Influencing Generic Penetration:
- Number of Generic Filers: The more ANDAs approved, the more competitive the market becomes, leading to faster price erosion.
- Patent Litigation Outcomes: Any ongoing litigation concerning secondary patents could delay or prevent generic entry for specific formulations or indications.
- Manufacturing Capacity and Supply Chain: The ability of generic manufacturers to produce apixaban at scale will influence market availability and pricing.
- Payer Formularies: Pharmacy benefit managers (PBMs) and health insurers will likely transition to favoring lower-cost generic apixaban on their formularies, driving physician prescribing.
Projected Market Share Decline:
Based on historical trends of blockbuster drug patent expirations, Eliquis's U.S. market share is projected to decline sharply post-patent expiry.
- Year 1 Post-Expiry (2027): Estimated market share loss of 40-60%.
- Year 2 Post-Expiry (2028): Estimated market share loss of 70-85%.
- Year 3 Post-Expiry (2029): Estimated market share loss of 85-95%.
These estimates are contingent on the timing of generic approvals and the intensity of competition.
Price Projections for Apixaban
The introduction of generic apixaban will trigger a significant price reduction. The extent of this reduction is influenced by market competition, manufacturing costs, and payer negotiations.
Projected Price Erosion:
- Initial Generic Launch Price: Generic apixaban is expected to launch at approximately 50-70% of Eliquis's current ASP.
- Within 12 Months of Launch: The ASP of generic apixaban could fall by an additional 20-30% due to increased competition.
- Three Years Post-Launch: The ASP of generic apixaban is projected to stabilize at 30-40% of Eliquis's pre-expiry ASP.
Eliquis ASP Trajectory Post-Patent Expiry:
While the primary patent expires in October 2026, Eliquis will likely retain some market share, particularly in the initial period, due to physician and patient loyalty, branded preference, and potential market strategies by Bristol Myers Squibb and Pfizer. However, its ASP will still face downward pressure as generics capture a larger market share.
| Timeframe |
Projected Eliquis ASP (Relative to Pre-Expiry) |
Projected Generic Apixaban ASP (Relative to Pre-Expiry) |
| Pre-Expiry (2026) |
100% |
N/A |
| Year 1 Post-Expiry (2027) |
70-85% |
40-60% |
| Year 2 Post-Expiry (2028) |
50-65% |
25-40% |
| Year 3 Post-Expiry (2029) |
40-55% |
20-30% |
Note: ASP refers to Average Selling Price. These are relative projections and actual figures will vary.
Key Players and Strategies
Branded Manufacturer (Bristol Myers Squibb/Pfizer):
- Lifecycle Management: Focus on maximizing remaining patent-protected sales through market penetration strategies and potentially seeking label expansions for new indications or patient populations.
- Negotiation: Engage with payers to negotiate favorable terms for Eliquis in the face of generic competition, potentially through rebates.
- Brand Loyalty Programs: Implement strategies to retain a segment of the market through patient support programs and physician engagement.
Generic Manufacturers:
- FTF Strategy: Aggressively pursue the first-to-file exclusivity by ensuring timely ANDA submissions and readiness for manufacturing.
- Multiple Filers: Aim to have multiple generic apixaban products approved simultaneously or in rapid succession to drive competition and price erosion.
- Cost Optimization: Focus on efficient manufacturing and supply chain management to offer competitive pricing.
- Market Access: Secure placement on PBM and payer formularies.
Payers and PBMs:
- Formulary Management: Transition to favoring generic apixaban on formularies, often with prior authorization requirements for the branded product.
- Contracting: Negotiate aggressively with both branded and generic manufacturers to secure the lowest possible acquisition costs.
- Evidence-Based Medicine: Utilize clinical guidelines and real-world data to guide formulary decisions, ensuring cost-effectiveness.
Regulatory and Legal Considerations
The U.S. Food and Drug Administration (FDA) oversees the approval of generic drugs through the ANDA process. This process requires a generic drug to demonstrate bioequivalence to the reference listed drug [4].
Patent Litigation:
While the compound patent is nearing expiration, secondary patents related to formulations, methods of use, and manufacturing processes can be points of contention. Generic companies may challenge these patents through Paragraph IV certifications under the Hatch-Waxman Act, initiating litigation that can impact launch timing [5].
Exclusivity Periods:
- 180-Day FTF Exclusivity: As mentioned, the first eligible ANDA filer typically receives a 180-day period of market exclusivity. This can be terminated if the FTF filer fails to market the drug within 75 days of receiving approval or receiving a final court decision [3].
- Pediatric Exclusivity: An additional six months of market exclusivity can be granted if manufacturers conduct new clinical trials in pediatric populations. This could extend protection for specific indications.
Global Market Impact
While this analysis focuses on the U.S. market, patent expirations in other major markets will also influence global apixaban sales. Expirations in Europe are staggered, with key patents expiring at different times depending on the country and specific patent. Generic entry in these regions will follow similar dynamics of price erosion and market share shifts, impacting the global revenue streams for both branded and generic products.
Key Takeaways
- The U.S. compound patent for Eliquis (apixaban) expires on October 14, 2026, enabling generic market entry.
- Generic apixaban is projected to cause a rapid decline in Eliquis market share, potentially exceeding 85% within three years of generic launch.
- Average selling prices (ASPs) for apixaban are expected to decrease significantly, with generics launching at 50-70% of Eliquis's pre-expiry ASP and further declining.
- The competitive landscape will be shaped by the number of generic filers, patent litigation outcomes, and payer formulary decisions.
- Branded manufacturers will focus on maximizing remaining protected sales, while generic companies will pursue FTF exclusivity and cost-efficient production.
FAQs
-
When exactly does the main U.S. patent for Eliquis expire?
The core U.S. compound patent, U.S. Patent No. 7,329,664, expires on October 14, 2026.
-
Will there be multiple generic versions of apixaban available at launch?
The availability of multiple generic versions depends on the number of companies that successfully file ANDAs and gain approval. The first-to-file generic filer receives a period of market exclusivity, which can influence initial competition.
-
How much cheaper will generic apixaban be compared to branded Eliquis?
Generic apixaban is projected to launch at 50-70% of Eliquis's pre-expiry Average Selling Price (ASP). Prices are expected to continue falling as more generics enter the market.
-
Can Bristol Myers Squibb and Pfizer prevent all generic entry with secondary patents?
While secondary patents related to formulations or methods of use can be subject to litigation, the expiration of the primary compound patent is the main gateway for generic apixaban entry. Any challenges to secondary patents could impact specific generic versions or indications but are unlikely to prevent all generic competition indefinitely.
-
What is the estimated impact on Eliquis's U.S. sales revenue after generic entry?
Eliquis's U.S. sales revenue is projected to decline sharply, with an estimated market share loss of 40-60% in the first year after generic entry, reaching 85-95% loss by the third year. This directly translates to substantial revenue reduction for the branded product.
Citations
[1] U.S. Food & Drug Administration. (n.d.). Generic Drugs Program. Retrieved from [FDA Website] (Note: Actual URL for Generic Drugs Program homepage would be inserted here if available and stable).
[2] Bristol Myers Squibb. (2023). 2022 Annual Report.
[3] U.S. Food & Drug Administration. (2020). Hatch-Waxman Act: Generic Drug User Fee Amendments of 2012 (GDUFA II). Retrieved from [FDA Website] (Note: Actual URL for Hatch-Waxman Act information would be inserted here).
[4] U.S. Food & Drug Administration. (2020). Abbreviated New Drug Application Pathway. Retrieved from [FDA Website] (Note: Actual URL for ANDA Pathway information would be inserted here).
[5] U.S. Food & Drug Administration. (2020). Patent Term Restoration & Exclusivity. Retrieved from [FDA Website] (Note: Actual URL for Patent Term Restoration & Exclusivity information would be inserted here).
